AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01211522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.
Study NCT03876782 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IOLMaster
Description: IOL power calculation will be done with IOLMaster
Study NCT03876782 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Verion
Description: IOL power calculation will be done with Verion
Study NCT04103385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE (Reconnecting to Internal Sensations and Experiences)
Description: The overarching goal of RISE is to increase interoception by reconnecting people with their internal sensations
Study NCT04103385 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RISE (Reconnecting to Individual Strength and Energy)
Description: Aims to reduce life stressors and improve physical health
Study NCT00210977 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. All participants will be maintained on their regular dose regimen of standard-of-care treatment, under the guidance of the treating physician/investigator.
Study NCT01558895 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Infrared ray heat treatment
Description: Patients in experimental group accepted Infrared ray heat treatment in hepatic area for 30 minutes as well as conventional therapy.
Study NCT01558895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: Conventional treatment consists of antiviral drugs, lowering aminotransferase and jaundice medicine.
Study NCT02647229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isosmotic bowel cleansing preparation
Description: Isosmotic Preps contain polyethylene glycol (PEG) and are osmotically balanced, high-volume, nonabsorbable, and nonfermentable electrolyte solutions.
Study NCT02647229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colonic Hyrdrotherapy
Description: FDA approved method of colon cleansing using constant warm water lavage with a contained temperature and pressure controlled device administered by a trained technician
Study NCT03107897 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-habilitation
Description: Eight - Twelve visits to physical therapy prior to their TAVR procedure.
Study NCT01131871 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Weight Loss Intervention
Description: Subjects in this group will receive our standard behavioral weight control program that is delivered in an in-person group-based format. At month 7 subjects will also be given access to a study website to monitor eating and activity behaviors, and to have electronic access to standardized intervention materials. At month 7 subjects will also receive targeted study-related text messages that otherwise would have been provided in paper format.
Study NCT01131871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Weight Loss Intervention
Description: Subjects in this group will participate in a weight loss intervention that includes technology enhancements. These enhancements will include the addition of intervention specific targeted and tailored text messaging and the BodyMedia Fit System® beginning at Month 7. At month 7 subjects in EWLI will also receive the same targeted study-related text messages provided to SBWP that otherwise would have been provided in paper format.
Study NCT02125708 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OvulaRing®
Description: The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. It was originally invented to assess the moment of ovulation and optimize fertility. This plastic ring including a high-tech-sensor thermometer should be placed into the vaginal fornix for a maximum of 30 days, measuring the intravaginal core-temperature 288 times a day.
Study NCT00517582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOE-140
Description: Subcutaneous at time 0 and 6 hours
Study NCT00517582 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous at time 0 and 6 hours
Study NCT04048954 — intervention group
Intervention type: DEVICE
Intervention: Applitabac
Description: Smartphone application in screening on tabagism complications
Study NCT03875677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS group
Description: 5 sintered Ag/AgCl ring electrodes will be used at a radius of \~5cm. The electrodes will be placed inside plastic electrode holders which will be filled with gel to have better contact with the scalp.
Study NCT03875677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional tDCS group
Description: A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
Study NCT03875677 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tDCS group
Description: A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
Study NCT01222260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Patients will start bendamustine at dose level 0 and according to CrCl on day 1 and 2 of each cycle:~* CrCl ≥ 60 mL/min: 100 mg/m2 IV on day 1 and 2 of each cycle~* CrCl 59 - 30 mL/min: 90 mg/m2 IV on day 1 and 2 of each cycle~Available to qualifying subjects is the option to dose escalate to dose level (+)1:~* 120 mg/m2 (if CrCl ≥ 60 mL/min at the time of inclusion into the study)~* 100 mg/m2 (if CrCl 59-30 mL/min at the time of inclusion into the study)
Study NCT01222260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg orally on days 1, 8, 15, 22 of each cycle
Study NCT03720197 — intervention group
Intervention type: OTHER
Intervention: Online questionnaire - Phase 1
Description: Draw an overall picture of the population with type 1 diabetes in Canada in terms of demographics, diabetes treatment, hypoglycemia frequency and diabetes complications.
Study NCT03720197 — intervention group
Intervention type: OTHER
Intervention: Online questionnaire - Phase 2
Description: Characterize the causes, experience and consequences of hypoglycemia.
Study NCT03720197 — intervention group
Intervention type: OTHER
Intervention: Online questionnaire - Phase 3
Description: Collect information on diabetes and hypoglycemia treatment, hyperglycemia management, sleep habits, depression, physical activity and the benefits of technologies to reduce the frequency of hypoglycemia.
Study NCT03720197 — intervention group
Intervention type: OTHER
Intervention: Food questionnaire
Description: 24-hour food recall questionnaire
Study NCT03720197 — intervention group
Intervention type: OTHER
Intervention: Pedometer
Description: Participants will wear a podometer for 14 consecutives days
Study NCT03720197 — intervention group
Intervention type: OTHER
Intervention: Waist circumference
Description: Participants will be asked to measure their waist circumference
Study NCT03720197 — intervention group
Intervention type: OTHER
Intervention: Blood and urine tests
Description: Participants will be invited to send us their latests blood and urine test results.
Study NCT03720197 — intervention group
Intervention type: OTHER
Intervention: List of medications
Description: Participants will be invited to send us their list of medications
Study NCT03720197 — intervention group
Intervention type: OTHER
Intervention: Continuous glucose monitor
Description: Participants will be invited to send us the latest report of their continuous glucose monitor
Study NCT05319275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyllevocarnitine Hydrochloride Tablets
Description: 500 mg (2×250 mg/tablet) after meal, 3 times per day
Study NCT05319275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg (2×250 mg/tablet) after meal, 3 times per day
Study NCT00593957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Subjects will be randomized to receive one of three dosage groups either 0.25 mg/kg per day; or 2.5 mg/kg/day; or 5mg/kg/day of Dextromethorphan Polistirex (Delsym)oral syrup, which will be given exactly 12 hours apart in two divided doses during the 6 month trial.
Study NCT00593957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Dextromethorphan polistirex. Doses are 0.25 mg/kg/day, 2.5mg/kg/day, and 5 mg/kg/day. The drug is given in two divided doses 12 hours apart for 6 months.
Study NCT04258436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior block
Description: Serratus anterior block will be performed using an ultrasound guided transducer to inject 2mg/kg of 0.2% ropivacaine
Study NCT02909400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH176
Study NCT02909400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02973048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyperbaric bupivacaine
Description: The dose of 10 mg of hyperbaric bupivacaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
Study NCT02973048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric prilocaine
Description: The dose of 50 mg of hyperbaric prilocaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
Study NCT01241097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin, combined with simvastatin ezetimibe, placebo
Description: simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
Study NCT04085315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib is a medication used to treat non-small-cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. Patients will be receiving full dose osimertinib (80 mg PO daily) as part of the patient's current standard of care.
Study NCT04085315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib is an orally available selective aurora A kinase inhibitor. Alisertib will be administered to eligible patients in combination with osimertinib at doses ranging from 20 mg to 50 mg PO twice daily on days 1-3, 8-10, and 15-17 of a 28-day cycle. The starting alisertib dose for Cohort 1 will be 30 mg twice daily (dose level 1).
Study NCT03511313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: After a renal angiography according to standard procedures, subjects are treated with renal denervation (with sterile irrigated deflectable ablation catheter in renal artery), if without renal anatomic abnormality not detected by Renal CT/CTA.
Study NCT03511313 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Renal angiography
Description: A renal angiography according to standard procedure.
Study NCT04281862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Study NCT04281862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Prednisolone
Description: Standard of care topical drop treatment
Study NCT01870518 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral GPi DBS
Study NCT03511313 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Renal angiography
Description: A renal angiography according to standard procedure.
Study NCT01870518 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral STN DBS
Study NCT02822638 — intervention group
Intervention type: OTHER
Intervention: STEMI PATIENT Cohort
Description: PCI
Study NCT01341353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter ablation
Description: circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
Study NCT01341353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
Study NCT01834989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin-like growth factor I
Study NCT00584597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline Control
Study NCT00584597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel S
Description: Traumeel S 1 mL
Study NCT00584597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel S
Description: Traumeel S 2mL
Study NCT00584597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel S
Description: Traumeel S 3mL
Study NCT04483986 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus muscle re-approximation
Description: Study group: we are going to re-approximate rectus muscle wirth minimum 3 stiches.
Study NCT03688607 — intervention group
Intervention type: PROCEDURE
Intervention: There will not be an intervention, rather the investigators will deploy best practices and track POKEs within the healthcare system to evaluate clinical and operational outcomes.
Description: There will not be an intervention, rather the investigators will deploy best practices and track POKEs within the healthcare system to evaluate clinical and operational outcomes.
Study NCT03634514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone - Biomatrop
Description: The subjects who recieve Biomatrop first, after a period maximum of 24 hours will recieve a dose of Hormotrop.
Study NCT03634514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human growth hormone - Biomatrop
Description: The subjects who recieve Biomatrop first, after a period maximum of 24 hours will recieve a dose of Hormotrop.
Study NCT03634514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone - Hormotrop
Description: The subjects who recieve Hormotrop first, after a period maximum of 24 hours will recieve a dose of Biomatrop.
Study NCT03634514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human growth hormone - Hormotrop
Description: The subjects who recieve Hormotrop first, after a period maximum of 24 hours will recieve a dose of Biomatrop.
Study NCT01115972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1585
Description: oral
Study NCT01115972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan
Description: oral
Study NCT00292461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide
Description: Tablet once or twice daily orally for 16 weeks
Study NCT00292461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Tablet once daily orally for 16 weeks
Study NCT02874339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen therapy
Description: In the optiflow group, oxygen will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs. Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance.
Study NCT02874339 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation
Description: In the NIV group, NIV will be delivered through a face mask connected to a ventilator with pressure support applied in a noninvasive ventilation mode. The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort.
Study NCT04568720 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: Isolated the blood sample and detected the CTC
Study NCT02867319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A dose of ACYW135 meningococcal polysaccharide vaccine
Description: A dose of ACYW135 meningococcal polysaccharide vaccine will be given in certain arm.
Study NCT03384654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participant will receive daratumumab 16 milligram per kilogram (mg/kg) in cohort 1 and cohort 2.
Study NCT03384654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Participant will receive vincristine 1.5 milligram per meter square (mg/m\^2) in cohort 1 and cohort 2.
Study NCT03384654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participant will receive prednisone 40 mg/m\^2 in cohort 1 and cohort 2.
Study NCT03384654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Participant will receive doxorubicin 60 mg/m\^2 in cohort 2.
Study NCT03384654 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peg-asparaginase
Description: Participant will receive peg-asparaginase 2500 units per meter square (U/m\^2) in cohort 2.
Study NCT03384654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participant will receive cyclophosphamide 1 gram per meter square (g/m\^2) once in cohort 2.
Study NCT03384654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Participant will receive cytarabine 75 mg/m\^2 in cohort 2.
Study NCT03384654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine
Description: Participant will receive 6-mercaptopurine 60 mg/m\^2 orally daily in cohort 2.
Study NCT03384654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participant will receive methotrexate 5 g/m\^2 intravenously (IV) in cohort 2.
Study NCT01210118 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low intensity intervention
Description: Control group participants received a face to face low intensity intervention which lasted 5 minutes and included brief advice and the provision of a leaflet on smoking and pregnancy. This leaflet summarized the main effects of smoking during pregnancy and gave clear short messages for encouraging smoking cessation by setting up a quit date.
Study NCT01210118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Higher intensity intervention
Description: Experimental group participants received a higher intensity intervention, which include: 30 minutes of individualized cognitive-behavioural counselling delivered by a trained health care professional and a self-help manual especially tailored for smoking cessation during pregnancy. Counseling was based at the 5 Αs (Ask,Advise, Asses, Assist, Arrange). In addition to counselling, a self help manual especially tailored for smoking cessation during pregnancy for Greek women was provided.
Study NCT04265833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: Biodentine has been shown to cause increased calcium ion release and this increase has been associated with the presence of pure tricalcium silicate and calcium chloride and the increased Ca(OH)2 formation
Study NCT04265833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraCal LC
Description: TheraCal LC (Bisco Inc, IL, USA) is a light-cured, resin-modified, calcium silicate-based material designed as a direct/indirect pulp-capping material. This agent has been shown to increase the pH on the pulpal surface thereby stimulating regenerative processes in the pulp, and ultimately contributing to the formation of dentin bridge
Study NCT04265833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: Calcium hydroxide (Ca\[OH\]2) is a successful pulp-capping agent activating the repair mechanism by stimulating the dentin-pulp complex. Ca(OH)2, with its bactericidal effects, protects the complex from bacterial effects and also has a stimulating effect on dentin remineralization
Study NCT02714387 — intervention group
Intervention type: OTHER
Intervention: Collection of medical data
Description: A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
Study NCT03911011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh air
Description: Fresh air insufflation of 2 L/min toward mouth/nose.
Study NCT03714425 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quell
Description: Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.